Xylazine Is Losing Ground in the Drug Supply. What's Replacing It Is Worse, and Naloxone Still Won't Touch Either One.

In Philadelphia’s drug supply, the sedative cutting fentanyl has almost completely turned over in under two years — and the replacement is more dangerous than what it replaced. Reporting in Healio tracked drug-checking samples from May 2024 to March 2026 and found medetomidine-positive samples rose from 29% to 90% of the supply, while xylazine-positive samples fell from 97% to 28% over the same window. Medetomidine is a veterinary sedative estimated to be 100 to 200 times more potent than xylazine by weight.

Scheduling xylazine didn’t shrink the supply of adulterant sedatives cut into fentanyl. It just handed the market a more dangerous one. Researchers studying the shift describe it as a textbook version of what drug-policy researchers call the “iron law of prohibition”: crack down on one substance in a black market and the market doesn’t shrink, it substitutes toward whatever’s harder to detect and regulate next — often something stronger, because potency is easier to smuggle than volume. That pattern isn’t new to this drug class specifically. It’s the same dynamic that took the opioid supply from prescription pills to heroin to fentanyl over the last two decades, each shift driven partly by enforcement pressure on the substance before it.

The part that should change what you carry, not just what you know: naloxone does not reverse a xylazine or medetomidine overdose. Both are alpha-2 agonists, a sedative class naloxone was never built to touch, which means a fentanyl-medetomidine mixture can keep someone unconscious and unable to breathe on their own well after naloxone has reversed the opioid component. That’s not a reason to skip naloxone — it’s still doing real work on the fentanyl side of nearly every mixed-supply overdose, and it’s still free and legal to carry. It’s a reason rescue breathing and staying with someone until EMS arrives matter as much as the reversal drug itself, especially anywhere medetomidine has already established itself in the local supply. Wound care matters too: xylazine was already notorious for causing severe skin ulcers at injection sites regardless of whether a person overdosed; researchers don’t yet know whether medetomidine carries the same risk, which is its own small, quiet argument for not assuming the old warnings still map cleanly onto the new sedative replacing it.

Nobody scheduled medetomidine into existence expecting it. It showed up because something did, right on schedule, and the supply moved on before the policy response caught up.